X4 Pharmaceuticals (XFOR) Revenue (2018 - 2025)
X4 Pharmaceuticals (XFOR) posted Revenue of $2.6 million for Q4 2025, up 45.5% on a QoQ basis from $1.8 million in Q3 2025, and up 79.08% year-over-year from $1.4 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Revenue (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals' Revenue history runs 4 years deep, the most recent figure standing at $2.6 million for Q4 2025.
- Quarterly Revenue rose 79.08% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.1 million (up 1273.21% YoY) and the FY2025 annual result came in at $35.1 million, up 1273.21% from the prior year.
- Revenue was $2.6 million for Q4 2025 at X4 Pharmaceuticals, up from $1.8 million in the prior quarter.
- Across five years, Revenue topped out at $28.8 million in Q1 2025 and bottomed at $560000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 1.17 Bn |
| 10 | X4 Pharmaceuticals | 165.79 Mn | -51.26 Mn | 2.20 Mn | 2.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 28.81 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 560,000.00 |
| Jun 30, 2024 | 563,000.00 |
| Mar 31, 2020 | 3.00 Mn |
| Dec 31, 2018 | 3.50 Mn |